On the Field with Will Levis

NFL Quarterback

ZO 7 21 23 EVO ICL WILL LEVIS 25

Will Levis’ struggle with glasses and contacts

As a quarterback for the University of Kentucky Wildcats, Will Levis knew the importance of clear vision. Every move, every pass, and every decision depended on it. But being nearsighted and wearing contact lenses posed challenges that often impacted his game.

“I've had to deal with glasses and contact lenses for my whole adolescent and adult life. I've even had my contact lenses knocked out during a game, taking away my ability during a play or a drive.”

When he was drafted by the Tennessee Titans in 2023, the stakes became even higher. Transitioning to professional football meant he couldn't afford any distractions, especially from his vision.

“I wanted to do what was best for me and have the best edge that I could get. When looking at all the options, it became clear that EVO ICL was the best option for me.”

0
ZO 7 21 23 EVO ICL WILL LEVIS 81

Why Will Levis chose EVO ICL lenses

When doing his research on EVO ICL, a couple of benefits stood out to Will:

  • Safety: Unlike other procedures, EVO ICL doesn’t involve the permanent removal of corneal tissue.
  • Comfort: The EVO ICL procedure doesn't cause dry eye syndrome.
  • Removability: EVO ICL lenses can be safely removed by a doctor if ever needed. This added flexibility gave Will peace of mind.

On the field, EVO ICL gives me more confidence in my game and my ability. EVO ICL lets me play more freely, not having to worry about the daily hassles that come with wearing contact lenses.”

My day-to-day life has changed drastically. Being able to wake up and see clearly right away is such an underrated aspect of life. The difference in my eyesight from before and after the EVO ICL procedure is night and day. I truly know that getting EVO ICL is one of the best decisions I've made in my entire life.

ZO 7 21 23 EVO ICL WILL LEVIS 60

Ready to Discover Visual Freedom With EVO ICL? Find a Doctor Today

Important Safety Information

It is important to consider that EVO Visian® Implantable Collamer Lenses (ICL) are approved by the local health authority, which means they have been determined to be safe and effective. As with any procedure, there are risks to consider. If you have any questions or concerns it is always best to speak with a certified EVO Visian® Implantable Collamer Lens (ICL) doctor. The EVO Visian ICL family of lenses include EVO Visian ICL, EVO Visian Toric ICL, EVO+ Visian ICL, and EVO+ Visian Toric ICL and are designed for the correction/reduction of low to high myopia (-0.5 to -20.0 diopters (D)) and the correction/reduction of myopia in patients with up to -20 D of myopia with less than or equal to 6.0 D of astigmatism. The EVO Visian ICL family is indicated for use in phakic eye treatment and for: The correction/reduction of myopia in adults 21 – 60 years of age with power ranging from -0.5 D to -20.0 D at the spectacle plane. With an anterior chamber depth (ACD) equal to or greater than 3.0 mm, as measured from the corneal endothelium to the anterior lens capsule. This extended age range covering over 45 to 60 years of age only applies to the myopic EVO Visian ICL family, and only in countries covered by the jurisdiction of the EU Notified Bodies where the CE Mark is recognised (i.e., the EU, EEA, and EFTA). The EVO Visian ICL family of products currently in inventory do not have the updated Directions For Use (DFU) with this new wording yet, but it will be incorporated over time. EVO Visian ICL surgery does not eliminate the need for reading glasses, even if you have never worn them before. The EVO Visian ICL represents an alternative to other refractive surgeries including, laser assisted in situ keratomileusis (LASIK), photorefractive keratectomy (PRK), incisional surgeries, or other means to correct myopia such as contact lenses and eye glasses. The EVO Visian Toric ICL is intended to correct or reduce astigmatism (up to 6.0 D) you may have (the EVO Visian ICL is not intended to treat your astigmatism). Implantation of an EVO Visian ICL is a surgical procedure, and as such, carries potentially serious risks. The following represent potential complications/adverse reactions reported in conjunction with refractive surgery in general: additional surgeries, cataract formation, loss of best corrected vision, raised pressure inside the eye, loss of cells on the innermost surface of the cornea, conjunctival irritation, acute corneal swelling, persistent corneal swelling, endophthalmitis (total eye infection), significant glare and/or halos around lights, hyphaema (blood in the eye), hypopyon (pus in the eye), eye infection, Visian ICL dislocation, macular oedema, non-reactive pupil, pupillary block glaucoma, severe inflammation of the eye, iritis, uveitis, vitreous loss and corneal transplant. Before considering EVO Visian ICL surgery you should have a complete eye examination and talk with your eye care professional about EVO Visian ICL surgery, especially the potential benefits, risks and complications. You should discuss the time needed for healing after surgery.

References

References

1. Patient Survey, STAAR Surgical ICL Data Registry, 2018

2. Sanders D. Vukich JA. Comparison of implantable collamer lens (ICL) and laser-assisted in situ keratomileusis (LASIK) for Low Myopia. Cornea. 2006 Dec; 25(10):1139-46. Patient Survey, STAAR Surgical ICL Data Registry, 2018

3. Naves, J.S. Carracedo, G. Cacho-Babillo, I. Diadenosine Nucleotid Measurements as Dry-Eye Score in Patients After LASIK and ICL Surgery. Presented at American Society of Cataract and Refractive Surgery (ASCRS) 2012.

4. Shoja, MR. Besharati, MR. Dry eye after LASIK for myopia: Incidence and risk factors. European Journal of Ophthalmology. 2007; 17(1): pp. 1-6.

5a. Lee, Jae Bum et al. Comparison of tear secretion and tear film instability after photorefractive keratectomy and laser in situ keratomileusis. Journal of Cataract & Refractive Surgery , Volume 26 , Issue 9 , 1326 - 1331.

5b. Parkhurst, G. Psolka, M. Kezirian, G. Phakic intraocular lens implantantion in United States military warfighters: A retrospective analysis of early clinical outcomes of the Visian ICL. J Refract Surg. 2011;27(7):473-481.

*American Refractive Surgery Council